Hercules Capital, Inc.
HTGCHercules Capital, Inc. (HTGC) is a specialty finance company that provides debt and equity financing to technology, life sciences, and broader venture growth companies. Founded in 2003, the firm primarily focuses on early and growth-stage companies, offering customized capital solutions to support their development and expansion efforts. Hercules Capital is known for its sector expertise and attention to innovation-driven markets.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| November 19, 2025 | $0.40 | 2025-11-12 | 2025-11-12 |
| November 19, 2025 | $0.07 | 2025-11-12 | 2025-11-12 |
| August 19, 2025 | $0.07 | 2025-08-12 | 2025-08-12 |
| August 19, 2025 | $0.40 | 2025-08-12 | 2025-08-12 |
| May 20, 2025 | $0.07 | 2025-05-13 | 2025-05-13 |
Dividends Summary
- Consistent Payer: Hercules Capital, Inc. has rewarded shareholders with 108 dividend payments over the past 20 years.
- Total Returned Value: Investors who held HTGC shares during this period received a total of $26.89 per share in dividend income.
- Latest Payout: The most recent dividend of $0.40/share was paid 65 days ago, on November 19, 2025.
- Yield & Schedule: HTGC currently pays dividends quarterly with an annual yield of 5.01%.
- Dividend Growth: Since 2005, the dividend payout has grown by 1500.0%, from $0.03 to $0.40.
Company News
MoonLake Immunotherapeutics reported Q3 2025 financial results, highlighting positive clinical trial data for its Nanobody® sonelokimab in treating inflammatory diseases like hidradenitis suppurativa, psoriatic arthritis, and palmoplantar pustulosis. The company ended the quarter with $380.5 million in cash and expects funding into the second ha...
Sound Income Strategies sold 177,473 shares of Hercules Capital for approximately $3.40 million in Q3 2025, reducing its stake while maintaining over 2.7 million shares. Hercules Capital has underperformed the S&P 500 over the past year.
Ashland Inc. announced Karl Bostaph's retirement as senior vice president of operations, with Wayne Muil taking over the role effective immediately. Muil brings over 25 years of global operations experience and will oversee Ashland's production facilities worldwide.
MoonLake Immunotherapeutics secures up to $500 million in non-dilutive financing from Hercules Capital, strengthening its financial position to advance its lead candidate sonelokimab. The company plans to provide clinical updates, including on its Phase 3 trials in hidradenitis suppurativa and Phase 2 trial in palmoplantar pustulosis.
The article recommends investing in three business development companies (BDCs) - Ares Capital, PennantPark Floating Rate Capital, and Hercules Capital - to generate $500 in annual dividend income by 2025 with an initial investment of $5,040. The BDCs offer high dividend yields ranging from 8.7% to 11.3%.
Related Companies
